Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing how two diabetes medications, GLP-1 receptor agonists and SGLT2 inhibitors, affect beta cell function in adults with type 2 diabetes over 16 weeks.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people Planned (estimated).

Who can join Ages 24–80 · all sexes

Timeline Started 2024-12 · est. completion 2028-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07325435 ↗

Description as written by the study sponsor.

Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people. Several recently approved diabetes medicines improve cardiovascular and renal outcomes through two different mechanisms. This study will explore key determinants of blood glucose levels namely beta cell function after short-term randomized, parallel group treatment with FDA approved Glucagon-Like Peptide-1 Receptor Agonists¬ (GLP-1 RA), or FDA approved Sodium-Glucose co-Transporter-2 Inhibitor (SGLT-2i). Because diabetes in black people shows a unique ability to recover pancreatic insulin secretion, it is important to determine whether the effects of these drug classes differentially improve pancreatic beta cell function.

Treatments tested

SGLT-2 inhibitor also known as empagliflozin (Jardiance®), dapagliflozin (Farxiga®), canagliflozin (Invokana®), bexagliflozin (Brenzavvy®) Drug

SGLT-2 inhibitors block the SGLT-2 receptor
GLP1-RA also known as liraglutide (Victoza), semaglutide (Ozempic), dulaglutide (Trulicity) Drug

GLP-1 RAs stimulate the GLP-1 Receptor

Main thing measured	Change in Stimulated C-peptide Index during an Oral Glucose Tolerance Test is a measure of Beta Cell Function and will be measuresd at baseline and at 16 weeks after treatment with GLP-1 Receptor Agonist or SGLT2-Inhibitor
Sponsor	MaryAnn Banerji
Conditions studied	Type 2 Diabetes (T2DM)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07325435 ↗